Relmada Therapeutics (RLMD)
(Delayed Data from NSDQ)
$3.46 USD
-0.04 (-1.14%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $3.48 +0.02 (0.58%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum C VGM
Relmada Therapeutics, Inc. (RLMD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.50 | $25.00 | $2.00 | 257.14% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Relmada Therapeutics, Inc. comes to $12.50. The forecasts range from a low of $2.00 to a high of $25.00. The average price target represents an increase of 257.14% from the last closing price of $3.50.
Analyst Price Targets (4 )
Broker Rating
Relmada Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 2.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 2.60 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, three are Strong Buy, representing 60% of all recommendations. A month ago, Strong Buy represented 40%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 2 | 2 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.20 | 2.20 | 2.60 | 2.60 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/7/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
7/8/2024 | Mizuho SecuritiesUSA | Uy D Ear | Not Available | Strong Buy |
6/5/2024 | Goldman Sachs | Andrea Tan | Hold | Strong Sell |
3/20/2024 | Guggenheim Securities | Yatin Suneja | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.20 |
ABR (Last week) | 2.20 |
# of Recs in ABR | 5 |
Average Target Price | $12.50 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 253 |
Current Quarter EPS Est: | -0.56 |
RLMD FAQs
Relmada Therapeutics, Inc. (RLMD) currently has an average brokerage recommendation (ABR) of 2.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for Relmada Therapeutics, Inc. (RLMD) is $12.50. The current on short-term price targets is based on 2 reports.
The forecasts for Relmada Therapeutics, Inc. (RLMD) range from a low of $2 to a high of $25. The average price target represents a increase of $261.27 from the last closing price of $3.46.
The current UPSIDE for Relmada Therapeutics, Inc. (RLMD) is 261.27%
Based on short-term price targets offered by four analysts, the average price target for Relmada Therapeutics, Inc. comes to $12.50. The forecasts range from a low of $2.00 to a high of $25.00. The average price target represents an increase of 257.14% from the last closing price of $3.50.